The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
 
Paul D. Nathan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Pierre Fabre; Roche
 
Jean Jacques Grob
Honoraria - Amgen; Brystol-Myers-Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Brystol-Myers-Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Brystol-Myers-Squibb; MSD; Novartis; Pierre Fabre
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Boguslawa Karaszewska
No Relationships to Disclose
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Eugeny Levchenko
Research Funding - AstraZeneca; MSD; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; MSD; Novartis; Roche
 
Vanna Chiarion Sileni
Consulting or Advisory Role - Brystol-Myers-Squibb; Merck Serono Serbia; MSD Oncology; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Brystol-Myers-Squibb; Novartis
Travel, Accommodations, Expenses - Brystol-Myers-Squibb
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Claus Garbe
Honoraria - Amgen; Brystol-Myers-Squibb; MSD; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Brystol-Myers-Squibb; MSD; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Roche; Sanofi
Research Funding - Brystol-Myers-Squibb (Inst); NeraCare GmbH (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Brystol-Myers-Squibb; MSD; NeraCare GmbH; Novartis; Philogen; Roche; Sanofi
 
Igor Bondarenko
No Relationships to Disclose
 
Michael A. Davies
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; NanoString Technologies; Novartis; Sanofi; Syndax; Vaccinex
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; ImaginAb; Lutris Pharma; Merus; PACT Pharma; Rgenix; Tango Therapeutics
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis
 
Keith Flaherty
Stock and Other Ownership Interests - Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; Fog Pharma; Fount Therapeutics; Loxo; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi; Vivid Biosciences; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Array BioPharma; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Cell Medica; Debiopharm Group; FOG Pharma; Genentech; Incyte; Lilly; Loxo; Merck; Neon Therapeutics; Novartis; Oncoceutics; Pierre Fabre; Roche; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi; Verastem
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - Debiopharm Group; Pierre Fabre
 
Paul Burgess
Employment - Novartis
Stock and Other Ownership Interests - GlaxoSmithKline
 
Monique Tan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Eduard Gasal
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grünenthal Group; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - 4SC; Amgen; Bristol-Myers Squibb; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)